2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre B
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

81 Glory interim analysis: A response-adapted glofitamab-based frontline strategy for older unfit or frail patients with diffuse large B-cell lymphoma

Pallawi Torka, MD, Nigel Gwini, MD2, Annie Qiu, MPH3, Regina Truong4, Helen Jacob5, Andrew Ip, MD, MS6, Suheil Albert Atallah-Yunes, MD7, Alexander P. Boardman, MD8, Philip Caron, MD9, Kevin David, MD10, Zachary Epstein-Peterson, MD11, Lorenzo Falchi, MD12, Paola Ghione, MD, MS13, Steven Horwitz, M.D.14, Andrew Intlekofer, MD, DPhil15, Anita Kumar, MD16, Jennifer Kimberly Lue, M.D.17, Efrat Luttwak, Luttwak, MD18, Alison Moskowitz, MD19, Ariela Noy, MD20, Colette Owens, MD21, Maria Lia Palomba, MD22, Mark Roschewski, MD23, Quinlan Sievers, MD, PhD24, Raphael Steiner, MD25, Robert Stuver, MD26, Santosha Vardhana, MD, PhD27, Jasmine Zain, M.D.28, Andrew Zelenetz, MD29, Alexander Koshy, MD30, Honglei Zhang, MD31, Venkatraman Seshan, PhD32, Gilles Salles I, MD, PhD33, Paul Hamlin, MD34
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 John Theurer Cancer Center - Oncology Center Hackensack University Medical Center, Hackensack, New Jersey, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Memorial Sloan Kettering Cancer Center, New York, New York, United States
31 Memorial Sloan Kettering Cancer Center, New York, New York, United States
32 Memorial Sloan Kettering Cancer Center, New York, New York, United States
33 Memorial Sloan Kettering Cancer Center, New York, New York, United States
34 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background:

Older adults (OA) with DLBCL classified as unfit or frail by simplified geriatric assessment (sGA) have poor outcomes with standard anthracycline-based chemotherapy. Bispecific antibodies (BsAb) demonstrate a favorable risk-benefit profile in OA, and their combination with chemotherapy may improve cure rates. Interim PET (iPET) has a high negative predictive value and can guide response-adapted therapy, reducing chemotherapy exposure in early responders.

GLORY is an investigator-initiated phase 2 study evaluating a window-style, glofitamab-based, response-adapted strategy with polatuzumab-rituximab-miniCHP (pola-R-miniCHP) backbone with the dual goal of improving response rates and reducing the anthracycline dosage required to achieve cure in unfit/frail OA with DLBCL. We report a planned interim analysis.

Methods:
This prospective, open label, dual institution study enrolled OA ≥ 65 years with newly diagnosed DLBCL, high grade, or transformed B-cell lymphoma, classified as unfit/frail by sGA. Following steroid pre-phase, patients received obinutuzumab (1000 mg) with polatuzumab (pola) 1.8 mg/kg on Cycle (C)1 day (D)1. Glofitamab (glofit) was administered with step-up dosing on C1D8 (2.5 mg), C1D15 (10 mg), and C2D1 (30 mg with pola). After two cycles of glofit plus pola, iPET2 guided therapy: patients with negative iPET2 (Deauville score 1-3) receive four cycles of glofit-pola-R-mini-CHP, whereas those with positive iPET2 without progressive disease (PD) receive 6 cycles. Patients with PD discontinued study treatment. Co-primary endpoints were complete response rate (CRR) at iPET2 and end-of-treatment (EOT). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Exploratory analyses included ctDNA dynamics and aging biomarkers.

Results:

As of July 1, 2026, 29 patients were enrolled. Median age was 81 years (72–93), 66% were ≥80 years, sGA unfit<80/unfit≥80/frail distribution was 34%/21%/45%. Additional characteristics included 72% Caucasian, 35% women, 50% ECOG PS 2, 69% stage IV, 52% GCB subtype, 66% IPI 3–5, 52% elevated LDH, 59% extranodal disease, and median diagnosis-to-treatment interval of 23 days (6–78).

The safety population included 26 patients receiving ≥1 study dose. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 24%. Two patients withdrew after C1D1 obinutuzumab (bowel perforation due to lymphoma, refusal of C1D8 admission) and were not evaluable for BsAb-related safety. The glofit-pola window was well tolerated, with no treatment delays or early progression. Adverse events of special interest included cytokine release syndrome grade 1/2 (21%/17%), neurotoxicity grade 1 (4%), neuropathy grade 1/2 (8%/8%), infusion reactions grade 1/2/3 (4%/23%/4%), and viral infections grade 1/2 (4%/4%). Grade 4 TRAE was neutropenia (n=1). Grade 3 TRAEs included anemia (n=1), neutropenia (n=1), colitis (n=1), diarrhea (n=1), hypotension (n=2), and infusion reaction (n=1). There were no on-treatment deaths. One patient died one month after therapy from non-neutropenic sepsis secondary to aspiration pneumonia and astrovirus colitis.

Efficacy evaluable population was defined by patients who received at least 1 full dose of glofit. At data cutoff, 21 and 14 patients were evaluable for iPET2 and EOT responses, respectively. At iPET2, ORR was 95.2% (20/21) and CRR was 52.4% (11/21), allowing chemotherapy reduction in over half the patients. One patient achieving CR at iPET2 required ileocecectomy for lymphoma-related bowel obstruction and continued glofit-pola-R. At EOT, ORR was 100% (14/14) and CRR was 85.7% (12/14). One patient initially classified as stable disease at iPET2 and EOT had biopsy-proven sarcoidosis, allowing response adjudication to CR. Median follow-up was 7.4 months (0–17), with no relapses observed.

Conclusion:
Interim analysis of GLORY demonstrates that frontline glofitamab plus polatuzumab is safe and highly active in sGA-defined unfit/frail OA with LBCL. More than half of patients achieved CR after only 2 cycles without early progression, enabling chemotherapy reduction. Response-adapted chemotherapy with glofit was well tolerated and resulted in high EOT CR rates. These findings indicate that BsAb-based combinations offer a personalized approach that may improve tolerability while maintaining curative potential with less reliance on anthracycline based therapy in this vulnerable population.

Pallawi Torka, MD: Abbvie - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Lilly Oncology - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)